Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Elliott Marshall Antman, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Elliott Antman and Robert Giugliano.
Elliott Antman
Connection Strength
10.999
Robert Giugliano
  1. Giugliano RP, Antman EM. Caeteris paribus - all things being equal. Eur Heart J. 2001 Dec; 22(24):2221-3.
    View in: PubMed
    Score: 0.270
  2. Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thromb Haemost. 2020 Sep 13.
    View in: PubMed
    Score: 0.248
  3. Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M, Duris T, Juul-Möller S, Voitk J, Trevisan M, Nordio F, Antman EM, Giugliano RP. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 01; 6(3):167-175.
    View in: PubMed
    Score: 0.245
  4. Dietz N, Ruff C, Giugliano RP, Mercuri MF, Antman EM. Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. Int J Cardiol. 2020 Oct 15; 317:159-166.
    View in: PubMed
    Score: 0.240
  5. Plitt A, Ruff CT, Goudev A, Morais J, Ostojic MC, Grosso MA, Lanz HJ, Park JG, Antman EM, Braunwald E, Giugliano RP. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2020 04 01; 304:185-191.
    View in: PubMed
    Score: 0.238
  6. Qamar A, Antman EM, Giugliano RP. Reply: Anticoagulants in Atrial Fibrillation and Liver Disease. J Am Coll Cardiol. 2019 11 12; 74(19):2436-2437.
    View in: PubMed
    Score: 0.234
  7. Bergmark BA, Kamphuisen PW, Wiviott SD, Ruff CT, Antman EM, Nordio F, Kuder JF, Mercuri MF, Lanz HJ, Braunwald E, Giugliano RP. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation. 2019 11 26; 140(22):1792-1801.
    View in: PubMed
    Score: 0.233
  8. Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension. 2019 09; 74(3):597-605.
    View in: PubMed
    Score: 0.230
  9. Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. J Am Coll Cardiol. 2019 07 16; 74(2):179-189.
    View in: PubMed
    Score: 0.229
  10. Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 05 14; 40(19):1541-1550.
    View in: PubMed
    Score: 0.226
  11. Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 05 14; 40(19):1518-1527.
    View in: PubMed
    Score: 0.226
  12. Steffel J, Ruff CT, Braunwald E, Hamershock RA, Murphy SA, Nieminen M, Lanz HJ, Mercuri MF, Peterson N, Antman EM, Giugliano RP. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace. 2019 Feb 01; 21(2):306-312.
    View in: PubMed
    Score: 0.222
  13. Correction. J Am Coll Cardiol. 2019 Feb 12; 73(5):627.
    View in: PubMed
    Score: 0.221
  14. Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP. Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.
    View in: PubMed
    Score: 0.218
  15. Yin OQP, Antman EM, Braunwald E, Mercuri MF, Miller R, Morrow D, Ruff CT, Truitt K, Weitz JI, Giugliano RP. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation. 2018 10 30; 138(18):1963-1973.
    View in: PubMed
    Score: 0.218
  16. Zelniker TA, Ruff CT, Antman EM, Giugliano RP. The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. Eur Heart J Acute Cardiovasc Care. 2019 Sep; 8(6):554-561.
    View in: PubMed
    Score: 0.217
  17. Corbalán R, Nicolau JC, López-Sendon J, Garcia-Castillo A, Botero R, Sotomora G, Horna M, Ruff CT, Hamershock RA, Grip LT, Antman EM, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol. 2018 09 25; 72(13):1466-1475.
    View in: PubMed
    Score: 0.217
  18. Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, Sritara P, Mercuri MF, Kamphuisen PW, Antman EM, Braunwald E, Giugliano RP. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial. J Am Heart Assoc. 2018 08 21; 7(16):e008987.
    View in: PubMed
    Score: 0.215
  19. Zelniker TA, Ruff CT, Wiviott SD, Blanc JJ, Cappato R, Nordio F, Mercuri MF, Lanz H, Antman EM, Braunwald E, Giugliano RP. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. Eur Heart J Acute Cardiovasc Care. 2019 Mar; 8(2):176-185.
    View in: PubMed
    Score: 0.214
  20. Douketis JD, Murphy SA, Antman EM, Grip LT, Mercuri MF, Ruff CT, Weitz JI, Braunwald E, Giugliano RP. Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thromb Haemost. 2018 06; 118(6):1001-1008.
    View in: PubMed
    Score: 0.211
  21. Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, Weitz JI, Ruff CT, Nordio F, Mercuri MF, Choi Y, Antman EM, Braunwald E, Giugliano RP. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e003998.
    View in: PubMed
    Score: 0.211
  22. Cavallari I, Ruff CT, Nordio F, Deenadayalu N, Shi M, Lanz H, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2018 04 15; 257:102-107.
    View in: PubMed
    Score: 0.207
  23. Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C, Chao TF, Le Heuzey JY, Mercuri M, Rutman H, Antman EM, Giugliano RP. Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017 Jun 30; 6(7).
    View in: PubMed
    Score: 0.199
  24. Steffel J, Ruff CT, Hamershock RA, Murphy SA, Senior R, Roy D, Lanz HJ, Mercuri MF, Antman EM, Giugliano RP. First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2017 Oct 01; 244:192-195.
    View in: PubMed
    Score: 0.198
  25. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol. 2017 Mar 21; 69(11):1372-1382.
    View in: PubMed
    Score: 0.195
  26. Ruff CT, Giugliano RP, Antman EM. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation. 2016 Jul 19; 134(3):248-61.
    View in: PubMed
    Score: 0.186
  27. Eisen A, Ruff CT, Braunwald E, Nordio F, Corbalán R, Dalby A, Dorobantu M, Mercuri M, Lanz H, Rutman H, Wiviott SD, Antman EM, Giugliano RP. Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 07 08; 5(7).
    View in: PubMed
    Score: 0.186
  28. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 05 20; 5(5).
    View in: PubMed
    Score: 0.184
  29. Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, Shi M, Mercuri MF, Antman EM, Braunwald E. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. Am J Med. 2016 Aug; 129(8):850-857.e2.
    View in: PubMed
    Score: 0.182
  30. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2288-95.
    View in: PubMed
    Score: 0.169
  31. O'Donoghue ML, Ruff CT, Giugliano RP, Murphy SA, Grip LT, Mercuri MF, Rutman H, Shi M, Kania G, Cermak O, Braunwald E, Antman EM. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. Eur Heart J. 2015 Jun 14; 36(23):1470-7.
    View in: PubMed
    Score: 0.169
  32. Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J, Grip L, Cange AL, Crompton AE, Murphy SA, Deenadayalu N, Antman EM. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014 Aug 12; 64(6):576-84.
    View in: PubMed
    Score: 0.163
  33. Ruff CT, Giugliano RP, Braunwald E, Antman EM. New oral anticoagulants in patients with atrial fibrillation - Authors'reply. Lancet. 2014 Jul 05; 384(9937):25-6.
    View in: PubMed
    Score: 0.162
  34. Giugliano RP, Ruff CT, Rost NS, Silverman S, Wiviott SD, Lowe C, Deenadayalu N, Murphy SA, Grip LT, Betcher JM, Duggal A, Dave J, Shi M, Mercuri M, Antman EM, Braunwald E. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke. 2014 Aug; 45(8):2372-8.
    View in: PubMed
    Score: 0.161
  35. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15; 383(9921):955-62.
    View in: PubMed
    Score: 0.155
  36. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28; 369(22):2093-104.
    View in: PubMed
    Score: 0.155
  37. Mogabgab O, Wiviott SD, Cannon CP, Sloan S, Sabatine MS, Antman EM, Braunwald E, Giugliano RP. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.
    View in: PubMed
    Score: 0.153
  38. Mogabgab O, Wiviott SD, Antman EM, Foody JM, Wang TY, Sabatine MS, Cannon CP, Li S, Giugliano RP. Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7.
    View in: PubMed
    Score: 0.148
  39. Giugliano RP, Giraldez RR, Morrow DA, Antman EM, Gibson CM, Mohanavelu S, Murphy SA, McCabe CH, Braunwald E. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Eur Heart J. 2010 Sep; 31(17):2103-10.
    View in: PubMed
    Score: 0.121
  40. Giraldez RR, Wiviott SD, Nicolau JC, Mohanavelu S, Morrow DA, Antman EM, Giugliano RP. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. Drugs. 2009 Jul 30; 69(11):1433-43.
    View in: PubMed
    Score: 0.115
  41. Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Shui A, Qin J, Scirica B, Bradner JE, Jang IK, Gibson CM, Antman EM. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007 Dec 15; 100(12):1734-8.
    View in: PubMed
    Score: 0.102
  42. Kashani A, Gibson CM, Murphy SA, Sabatine MS, Morrow DA, Antman EM, Giugliano RP. Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):228-33.
    View in: PubMed
    Score: 0.084
  43. Giugliano RP, Sabatine MS, Gibson CM, Roe MT, Harrington RA, Murphy SA, Morrow DA, Antman EM, Braunwald E. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.
    View in: PubMed
    Score: 0.080
  44. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003 Jun; 15(3):189-96.
    View in: PubMed
    Score: 0.075
  45. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA. 2003 Jan 15; 289(3):331-42.
    View in: PubMed
    Score: 0.073
  46. Antman EM, Cooper HA, Gibson CM, de Lemos JA, McCabe CH, Giugliano RP, Coussement P, Murphy S, Scherer J, Anderson K, Van de Werf F, Braunwald E. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Eur Heart J. 2002 Jun; 23(12):928-33.
    View in: PubMed
    Score: 0.070
  47. Giugliano RP, Llevadot J, Wilcox RG, Gurfinkel EP, McCabe CH, Charlesworth A, Thompson SL, Antman EM, Braunwald E. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J. 2001 Sep; 22(18):1702-15.
    View in: PubMed
    Score: 0.066
  48. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA. 2001 Jul 25; 286(4):442-9.
    View in: PubMed
    Score: 0.066
  49. Giugliano RP, McCabe CH, Antman EM, Cannon CP, Van de Werf F, Wilcox RG, Braunwald E. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001 May; 141(5):742-50.
    View in: PubMed
    Score: 0.065
  50. Antman EM, Gibson CM, de Lemos JA, Giugliano RP, McCabe CH, Coussement P, Menown I, Nienaber CA, Rehders TC, Frey MJ, Van der Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J. 2000 Dec; 21(23):1944-53.
    View in: PubMed
    Score: 0.063
  51. Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, Gibson CM, Newby LK, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O'Donoghue ML. Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022.
    View in: PubMed
    Score: 0.059
  52. Holper EM, Giugliano RP, Antman EM. Glycoprotein IIb/IIIa inhibitors in acute ST segment elevation myocardial infarction. Coron Artery Dis. 1999 Dec; 10(8):567-73.
    View in: PubMed
    Score: 0.059
  53. Inciardi RM, Giugliano RP, Claggett B, Gupta DK, Chandra A, Ruff CT, Antman EM, Mercuri MF, Grosso MA, Braunwald E, Solomon SD. Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. Eur J Heart Fail. 2019 12; 21(12):1571-1579.
    View in: PubMed
    Score: 0.059
  54. Gibson CM, Ryan KA, Kelley M, Rizzo MJ, Mesley R, Murphy S, Swanson J, Marble SJ, Dodge JT, Giugliano RP, Cannon CP, Antman EM. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group. Am Heart J. 1999 Jun; 137(6):1179-84.
    View in: PubMed
    Score: 0.057
  55. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999 Jun 01; 99(21):2720-32.
    View in: PubMed
    Score: 0.057
  56. Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019 02 05; 139(6):760-771.
    View in: PubMed
    Score: 0.056
  57. Wang K, Li H, Kwong WJ, Antman EM, Ruff CT, Giugliano RP, Cohen DJ, Magnuson EA. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017 Aug 11; 6(8).
    View in: PubMed
    Score: 0.050
  58. Fanola CL, Giugliano RP, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman EM, Braunwald E. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J. 2017 Mar 21; 38(12):888-896.
    View in: PubMed
    Score: 0.049
  59. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017 03 28; 135(13):1273-1275.
    View in: PubMed
    Score: 0.048
  60. Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol. 2017 01; 10(1).
    View in: PubMed
    Score: 0.048
  61. Ruff CT, Giugliano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, Mercuri M, Antman EM, Morrow DA. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2016 Dec 01; 1(9):999-1006.
    View in: PubMed
    Score: 0.048
  62. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol. 2016 09 13; 68(11):1169-1178.
    View in: PubMed
    Score: 0.047
  63. Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, Silverman S, Singhal AB, Nicolau JC, SomaRaju B, Mercuri MF, Antman EM, Braunwald E. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 2016 08; 47(8):2075-82.
    View in: PubMed
    Score: 0.046
  64. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016 Jul 05; 134(1):24-36.
    View in: PubMed
    Score: 0.046
  65. Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016 09; 18(9):1153-61.
    View in: PubMed
    Score: 0.046
  66. Gupta DK, Giugliano RP, Ruff CT, Claggett B, Murphy S, Antman E, Mercuri MF, Braunwald E, Solomon SD. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. J Am Soc Echocardiogr. 2016 06; 29(6):537-44.
    View in: PubMed
    Score: 0.046
  67. Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M, Antman EM, Braunwald E. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc. 2016 Feb 23; 5(2).
    View in: PubMed
    Score: 0.045
  68. Eisen A, Giugliano RP, Ruff CT, Nordio F, Gogia HS, Awasty VR, Henderson DA, Mercuri MF, Rutman H, Antman EM, Braunwald E. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Am Heart J. 2016 Feb; 172:144-51.
    View in: PubMed
    Score: 0.045
  69. Magnuson EA, Vilain K, Wang K, Li H, Kwong WJ, Antman EM, Ruff CT, Giugliano RP, Cohen DJ. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. Am Heart J. 2015 Dec; 170(6):1140-50.
    View in: PubMed
    Score: 0.044
  70. Geller BJ, Giugliano RP, Braunwald E, Murphy SA, Hanyok JJ, Jin J, Mercuri M, Antman EM, Ruff CT. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J. 2015 Oct; 170(4):669-74.
    View in: PubMed
    Score: 0.043
  71. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, Camm AJ, Antman EM, Ruff CT. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015 Sep 01; 36(33):2239-45.
    View in: PubMed
    Score: 0.043
  72. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2280-7.
    View in: PubMed
    Score: 0.042
  73. Gupta DK, Shah AM, Giugliano RP, Ruff CT, Antman EM, Grip LT, Deenadayalu N, Hoffman E, Patel I, Shi M, Mercuri M, Mitrovic V, Braunwald E, Solomon SD. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J. 2014 Jun 07; 35(22):1457-65.
    View in: PubMed
    Score: 0.039
  74. Bohula May EA, Bonaca MP, Jarolim P, Antman EM, Braunwald E, Giugliano RP, Newby LK, Sabatine MS, Morrow DA. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014 Jan; 60(1):158-64.
    View in: PubMed
    Score: 0.038
  75. Mogabgab O, Giugliano RP, Sabatine MS, Cannon CP, Mohanavelu S, Wiviott SD, Antman EM, Braunwald E. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.
    View in: PubMed
    Score: 0.036
  76. Leonardi S, Thomas L, Neely ML, Tricoci P, Lopes RD, White HD, Armstrong PW, Giugliano RP, Antman EM, Califf RM, Newby LK, Mahaffey KW. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. J Am Coll Cardiol. 2012 Dec 04; 60(22):2296-304.
    View in: PubMed
    Score: 0.036
  77. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012 May; 107(5):925-36.
    View in: PubMed
    Score: 0.034
  78. Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, Dalby AJ, Montalescot G, Braunwald E. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011 Jun 14; 123(23):2681-9.
    View in: PubMed
    Score: 0.033
  79. Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H, Merkely B, Baracioli L, Schersten F, Seabro-Gomes R, Braunwald E, Wiviott SD. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol. 2012 Mar 22; 155(3):424-9.
    View in: PubMed
    Score: 0.031
  80. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010 Oct; 160(4):635-41.
    View in: PubMed
    Score: 0.031
  81. Pride YB, Tung P, Mohanavelu S, Zorkun C, Wiviott SD, Antman EM, Giugliano R, Braunwald E, Gibson CM. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. JACC Cardiovasc Interv. 2010 Aug; 3(8):806-11.
    View in: PubMed
    Score: 0.031
  82. Morrow DA, Antman EM, Fox KA, White HD, Giugliano R, Murphy SA, McCabe CH, Braunwald E. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. Eur Heart J. 2010 Sep; 31(17):2097-102.
    View in: PubMed
    Score: 0.030
  83. Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BM. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
    Score: 0.030
  84. Ahmed S, Cannon CP, Giugliano RP, Murphy SA, Morrow DA, Antman EM, Braunwald E, Gibson CM. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17; 131(1):105-12.
    View in: PubMed
    Score: 0.026
  85. Scirica BM, Morrow DA, Sadowski Z, Ruda M, Nicolau JC, Giugliano RP, Wiviott SD, Sabatine MS, Shui A, Antman EM, Braunwald E. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6.
    View in: PubMed
    Score: 0.025
  86. Dumaine R, Gibson CM, Murphy SA, Southard M, Ly HQ, McCabe CH, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May; 8(5):315-22.
    View in: PubMed
    Score: 0.023
  87. Ahmed S, Antman EM, Murphy SA, Giugliano RP, Cannon CP, White H, Morrow DA, Braunwald E. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr; 21(2):119-29.
    View in: PubMed
    Score: 0.023
  88. Kirtane AJ, Kosmidou I, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CM. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am J Cardiol. 2005 Feb 01; 95(3):337-42.
    View in: PubMed
    Score: 0.021
  89. Ly HQ, Kirtane AJ, Buros J, Giugliano RP, Popma JJ, Antman EM, Harrington RA, Ohman EM, Gibson CM. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Feb 01; 95(3):383-6.
    View in: PubMed
    Score: 0.021
  90. Gibson CM, Kirtane AJ, Boundy K, Ly H, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 01; 45(3):357-62.
    View in: PubMed
    Score: 0.021
  91. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Roe MT, Harrington RA, Ohman EM, Braunwald E, Gibson CM. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.
    View in: PubMed
    Score: 0.021
  92. Kirtane AJ, Weisbord A, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Ohman EM, Roe MT, Braunwald E, Gibson CM. Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):224-7.
    View in: PubMed
    Score: 0.021
  93. Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, Cannon CP, Braunwald E, Gibson CM. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Dec 01; 94(11):1406-10.
    View in: PubMed
    Score: 0.021
  94. Karmpaliotis D, Turakhia MP, Kirtane AJ, Murphy SA, Kosmidou I, Morrow DA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CM. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Nov 01; 94(9):1113-7.
    View in: PubMed
    Score: 0.021
  95. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005.
    View in: PubMed
    Score: 0.021
  96. Kashani A, Giugliano RP, Antman EM, Morrow DA, Gibson CM, Murphy SA, Braunwald E. Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. Eur Heart J. 2004 Oct; 25(19):1702-10.
    View in: PubMed
    Score: 0.021
  97. Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Sep 01; 44(5):980-7.
    View in: PubMed
    Score: 0.020
  98. Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, Gibson CM, McCabe CH, Cannon CP, Antman EM, Braunwald E. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9.
    View in: PubMed
    Score: 0.020
  99. Gibson CM, Murphy SA, Morrow DA, Aroesty JM, Gibbons RJ, Gourlay SG, Barron HV, Giugliano RP, Antman EM, Braunwald E. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J. 2004 Aug; 148(2):336-40.
    View in: PubMed
    Score: 0.020
  100. Gardner GS, Frisch DR, Murphy SA, Kirtane AJ, Giugliano RP, Antman EM, Braunwald E, Gibson CM. Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. Am J Cardiol. 2004 Jul 15; 94(2):178-81.
    View in: PubMed
    Score: 0.020
  101. Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM. Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. Am J Cardiol. 2004 Jul 01; 94(1):108-11.
    View in: PubMed
    Score: 0.020
  102. Morrow DA, Antman EM, Murphy SA, Assmann SF, Giugliano RP, Cannon CP, Michael Gibson C, McCabe CH, Barron HV, Van De Werf F, Braunwald E. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004 Jul; 25(13):1139-45.
    View in: PubMed
    Score: 0.020
  103. Kirtane AJ, Bui A, Murphy SA, Karmpaliotis D, Kosmidou I, Boundy K, Rahman A, Pinto DS, Aroesty JM, Giugliano RP, Cannon CP, Antman EM, Gibson CM. Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. J Thromb Thrombolysis. 2004 Jun; 17(3):177-84.
    View in: PubMed
    Score: 0.020
  104. Gibson CM, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.
    View in: PubMed
    Score: 0.020
  105. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.
    View in: PubMed
    Score: 0.020
  106. Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80.
    View in: PubMed
    Score: 0.020
  107. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 05; 42(9):1535-43.
    View in: PubMed
    Score: 0.019
  108. Gibson CM, Gibson WJ, Murphy SA, Marble SJ, McCabe CH, Turakhia MP, Kirtane AJ, Karha J, Aroesty JM, Giugliano RP, Antman EM. Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. Am J Cardiol. 2003 Sep 01; 92(5):595-7.
    View in: PubMed
    Score: 0.019
  109. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP, Antman EM, Braunwald E. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 02; 42(1):7-16.
    View in: PubMed
    Score: 0.019
  110. Morrow DA, Antman EM, Sayah A, Schuhwerk KC, Giugliano RP, deLemos JA, Waller M, Cohen SA, Rosenberg DG, Cutler SS, McCabe CH, Walls RM, Braunwald E. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol. 2002 Jul 03; 40(1):71-7.
    View in: PubMed
    Score: 0.018
  111. Sabatine MS, McCabe CH, Morrow DA, Giugliano RP, de Lemos JA, Cohen M, Antman EM, Braunwald E. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 2002 Jun; 143(6):966-70.
    View in: PubMed
    Score: 0.017
  112. Morrow DA, Antman EM, Giugliano RP, Cairns R, Charlesworth A, Murphy SA, de Lemos JA, McCabe CH, Braunwald E. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet. 2001 Nov 10; 358(9293):1571-5.
    View in: PubMed
    Score: 0.017
  113. Llevadot J, Giugliano RP, Antman EM, Wilcox RG, Gurfinkel EP, Henry T, McCabe CH, Charlesworth A, Thompson S, Nicolau JC, Tebbe U, Sadowski Z, Braunwald E. Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. Eur Heart J. 2001 Nov; 22(22):2104-15.
    View in: PubMed
    Score: 0.017
  114. Schweiger MJ, Cannon CP, Murphy SA, Gibson CM, Cook JR, Giugliano RP, Changezi HU, Antman EM, Braunwald E. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001 Oct 15; 88(8):831-6.
    View in: PubMed
    Score: 0.017
  115. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald E. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19; 286(11):1356-9.
    View in: PubMed
    Score: 0.017
  116. de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Rifai N, Tanasijevic M, Giugliano RP, Schuhwerk KC, McCabe CH, Cannon CP, Antman EM, Braunwald E. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001 Aug 15; 88(4):353-8.
    View in: PubMed
    Score: 0.017
  117. de Lemos JA, Antman EM, Giugliano RP, Morrow DA, McCabe CH, Cutler SS, Charlesworth A, Schröder R, Braunwald E. Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II. Am J Cardiol. 2000 Dec 01; 86(11):1235-7, A5.
    View in: PubMed
    Score: 0.016
  118. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000 Oct 24; 102(17):2031-7.
    View in: PubMed
    Score: 0.016
  119. De Lemos JA, Antman EM, Giugliano RP, Morrow DA, McCabe CH, Charlesworth A, Schröder R, Braunwald E. Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. Am Heart J. 2000 Sep; 140(3):373-8.
    View in: PubMed
    Score: 0.015
  120. de Lemos JA, Antman EM, Morrow DA, Llevadot J, Giugliano RP, Coulter SA, Schuhwerk KC, Arslanian S, McCabe CH, Gibson CM, Rifai N. Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy. Clin Chim Acta. 2000 Aug; 298(1-2):85-97.
    View in: PubMed
    Score: 0.015
  121. Llevadot J, Giugliano RP, McCabe CH, Cannon CP, Antman EM, Murphy S, Gibson CM. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). Am J Cardiol. 2000 Jun 15; 85(12):1409-13.
    View in: PubMed
    Score: 0.015
  122. Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AA, Gibson CM, Giugliano RP, Mascelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NS. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Jun 13; 101(23):2690-5.
    View in: PubMed
    Score: 0.015
  123. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F, Gibson CM, Braunwald E. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol. 2000 Feb 01; 85(3):299-304.
    View in: PubMed
    Score: 0.015
  124. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Coulter SA, Anderson K, Scherer J, Frey MJ, Van Der Wieken R, Van De Werf F, Braunwald E. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000 Jan 25; 101(3):239-43.
    View in: PubMed
    Score: 0.015
  125. Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M, Frey MJ, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, Braunwald E. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1403-12.
    View in: PubMed
    Score: 0.015
  126. Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999 Oct; 34(4):974-82.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2020 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.